Similarly, in response to combination anti-PD-1 Ab + chidamide (12.5 mg/kg) + celecoxib (25 mg/kg) treatment, mice with CT26 tumors revealed reduced progression of all primary tumors, eradication of primary tumors in 3 out of 7 mice, and 71% survival at day 53 after tumor implantation (Fig. 1B–D). This evidence concerns the gene PDCD1 and neoplasm.